Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Astria Therapeutics (DE:2090)
MUNICH:2090
RESEARCH TOOLSreports
Astria Therapeutics (2090) Stock Price & Analysis
1 Followers
2090 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€4.74 - €4.74
Previous Close€4.74
Volume0.00
Average Volume (3M)N/A
Market Cap
€494.24M
Enterprise Value€317.69M
Total Cash (Recent Filing)$188.81M
Total Debt (Recent Filing)$488.00K
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 09, 2024EPS Estimate
-€0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-7.66
Forecast
1Y Price Target
€22.11Price Target Upside366.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Astria Therapeutics News
PremiumCompany Announcements
Astria Therapeutics Expands Board, Appoints New Director
PremiumCompany Announcements
Astria Therapeutics, Inc. Is Worried About This – Should You Be Worried Too?
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsSTAR-0215 demonstrates better efficacy on four hereditary angioedema measures compared to the market leader, potentially improving patient adherence and quality of life.
Drug Efficacy And ConvenienceTreatment with STAR-0215 was overall well-tolerated with no injection site reactions of pain, offering a potential tolerability advantage over existing treatments.
Financial PositionCompany is in a strong financial position, with STAR-0310 adding to the pipeline, representing an upside potential to valuation and overall investment case.
Bears Say
Clinical Trial RisksThere is downside risk to the approximately $6 per share level with a complete miss in the expected outcomes from the ALPHA-STAR readout.
Financial PerformanceShares are down significantly in comparison to the sector since the announcement of POC data.
Stock DilutionRecent equity raises and dilutive share counts could impact valuation negatively.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
4.24% Other Institutional Investors
95.76% Public Companies and
Individual Investors
2090 FAQ
What was Astria Therapeutics’s price range in the past 12 months?
Astria Therapeutics lowest stock price was €4.74 and its highest was €4.74 in the past 12 months.
What is Astria Therapeutics’s market cap?
Currently, no data Available
When is Astria Therapeutics’s upcoming earnings report date?
Astria Therapeutics’s upcoming earnings report date is May 09, 2024 which is in 13 days.
How were Astria Therapeutics’s earnings last quarter?
Astria Therapeutics released its earnings results on Mar 04, 2024. The company reported -€0.806 earnings per share for the quarter, missing the consensus estimate of -€0.731 by -€0.075.
Is Astria Therapeutics overvalued?
According to Wall Street analysts Astria Therapeutics’s price is currently Undervalued.
Does Astria Therapeutics pay dividends?
Astria Therapeutics does not currently pay dividends.
What is Astria Therapeutics’s EPS estimate?
Astria Therapeutics’s EPS estimate is -€0.32.
How many shares outstanding does Astria Therapeutics have?
Currently, no data Available
What happened to Astria Therapeutics’s price movement after its last earnings report?
Astria Therapeutics reported an EPS of -€0.806 in its last earnings report, missing expectations of -€0.731. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Astria Therapeutics?
Among the largest hedge funds holding Astria Therapeutics’s share is Perceptive Advisors LLC. It holds Astria Therapeutics’s shares valued at 31M.
---
Astria Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€22.11 (366.47% Upside)
€22.11 (366.47% Upside)
Blogger Sentiment
Bearish
DE:2090 Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $30.0M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.94%
12-Months-Change
Fundamentals
Return on Equity
-31.40%
Trailing 12-Months
Asset Growth
10.42%
Trailing 12-Months
Company Description
Astria Therapeutics
Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy. The company was founded by Michael R. Jirousek, Jill C. Milne, and Steven E. Shoelson on June 26, 2008 and is headquartered in Cambridge, MA.
---
2090 Company Deck
---
2090 Earnings Call
Q3 2023
0:00 / 0:00
---
2090 Stock 12 Months Forecast
Average Price Target
€22.11
▲(366.47% Upside)
Technical Analysis
Astria Therapeutics
―
Ultragenyx Pharmaceutical
―
Alnylam Pharma
―
Arcturus Therapeutics
―
Sarepta Therapeutics
―
Best Analysts Covering 2090
1 Year
1 Year Success Rate
9/16 ratings generated profit
1 Year Average Return
+21.32%
reiterated a buy rating last month
Copying Michael Higgins's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of +21.32% per trade.
---